ArticleBioMed research international2018
Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis.
Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Alpha-Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle.Neuropathology and applied neurobiology · 2025Article
- Inclusion Body Myositis: A Case Report.Cureus · 2025Article
- Intramyocardial fatty infiltration lesion in sporadic inclusion body myositis: a case report.The international journal of cardiovascular imaging · 2025Article
- Current biomarkers in inclusion body myositis.Journal of neuromuscular diseases · 2024Review
- Effects of sporadic inclusion body myositis on skeletal muscle fibre type specific morphology and markers of regeneration and inflammation.Rheumatology international · 2024Article
- Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases.Acta neuropathologica · 2024Review
- Whole-body muscle magnetic resonance imaging in inflammatory myopathy with mitochondrial pathology.Frontiers in neurology · 2024Article
- COVID-19-Induced Sporadic Inclusion Body Myositis.Cureus · 2022Article
- Inflammatory myopathies: an update for neurologists.Arquivos de neuro-psiquiatria · 2022Review
- Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies.Frontiers in immunology · 2021Review
- The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2020Review
- Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography.Journal of neurology · 2020Article
- Skewed macrophage polarization in aging skeletal muscle.Aging cell · 2019Article
- Clinical and molecular findings in a cohort of ANO5-related myopathy.Annals of clinical and translational neurology · 2019Article
- Diagnostic Imaging of Inflammatory Myopathies: New Concepts and a Radiological Approach.Current rheumatology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sporadic inclusion body myositis (sIBM) is considered the most common acquired myopathy aged over 50 years. The disease is characterized by a particular process of muscle degeneration characterized by abnormal deposit of protein aggregates in association with inflammation. The aim of this study was to present clinical and muscle histopathological findings, including immunostaining for LC3B, p62,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.